1079 related articles for article (PubMed ID: 31699883)
1. Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion.
Leone RD; Zhao L; Englert JM; Sun IM; Oh MH; Sun IH; Arwood ML; Bettencourt IA; Patel CH; Wen J; Tam A; Blosser RL; Prchalova E; Alt J; Rais R; Slusher BS; Powell JD
Science; 2019 Nov; 366(6468):1013-1021. PubMed ID: 31699883
[TBL] [Abstract][Full Text] [Related]
2. Tumor Microenvironment, Metabolism, and Immunotherapy.
DeBerardinis RJ
N Engl J Med; 2020 Feb; 382(9):869-871. PubMed ID: 32101671
[No Abstract] [Full Text] [Related]
3. Chronic Adrenergic Stress Contributes to Metabolic Dysfunction and an Exhausted Phenotype in T Cells in the Tumor Microenvironment.
Qiao G; Chen M; Mohammadpour H; MacDonald CR; Bucsek MJ; Hylander BL; Barbi JJ; Repasky EA
Cancer Immunol Res; 2021 Jun; 9(6):651-664. PubMed ID: 33762351
[TBL] [Abstract][Full Text] [Related]
4. Sialic Acid Blockade Suppresses Tumor Growth by Enhancing T-cell-Mediated Tumor Immunity.
Büll C; Boltje TJ; Balneger N; Weischer SM; Wassink M; van Gemst JJ; Bloemendal VR; Boon L; van der Vlag J; Heise T; den Brok MH; Adema GJ
Cancer Res; 2018 Jul; 78(13):3574-3588. PubMed ID: 29703719
[TBL] [Abstract][Full Text] [Related]
5. Treatment-enhanced CD4+Foxp3+ glucocorticoid-induced TNF receptor family related high regulatory tumor-infiltrating T cells limit the effectiveness of cytokine-based immunotherapy.
Berhanu A; Huang J; Watkins SC; Okada H; Storkus WJ
J Immunol; 2007 Mar; 178(6):3400-8. PubMed ID: 17339434
[TBL] [Abstract][Full Text] [Related]
6. Selective glutamine metabolism inhibition in tumor cells improves antitumor T lymphocyte activity in triple-negative breast cancer.
Edwards DN; Ngwa VM; Raybuck AL; Wang S; Hwang Y; Kim LC; Cho SH; Paik Y; Wang Q; Zhang S; Manning HC; Rathmell JC; Cook RS; Boothby MR; Chen J
J Clin Invest; 2021 Feb; 131(4):. PubMed ID: 33320840
[TBL] [Abstract][Full Text] [Related]
7. Adoptive transfer of ex vivo-activated memory T-cell subsets with cyclophosphamide provides effective tumor-specific chemoimmunotherapy of advanced metastatic murine melanoma and carcinoma.
Gold JE; Zachary DT; Osband ME
Int J Cancer; 1995 May; 61(4):580-6. PubMed ID: 7759164
[TBL] [Abstract][Full Text] [Related]
8. A
Kjaergaard J; Hatfield S; Jones G; Ohta A; Sitkovsky M
J Immunol; 2018 Jul; 201(2):782-791. PubMed ID: 29802128
[TBL] [Abstract][Full Text] [Related]
9. Administration of 6-gingerol greatly enhances the number of tumor-infiltrating lymphocytes in murine tumors.
Ju SA; Park SM; Lee YS; Bae JH; Yu R; An WG; Suh JH; Kim BS
Int J Cancer; 2012 Jun; 130(11):2618-28. PubMed ID: 21792901
[TBL] [Abstract][Full Text] [Related]
10. Reversing tumor immune suppression with intratumoral IL-12: activation of tumor-associated T effector/memory cells, induction of T suppressor apoptosis, and infiltration of CD8+ T effectors.
Kilinc MO; Aulakh KS; Nair RE; Jones SA; Alard P; Kosiewicz MM; Egilmez NK
J Immunol; 2006 Nov; 177(10):6962-73. PubMed ID: 17082611
[TBL] [Abstract][Full Text] [Related]
11. Reinforce the antitumor activity of CD8
Nabe S; Yamada T; Suzuki J; Toriyama K; Yasuoka T; Kuwahara M; Shiraishi A; Takenaka K; Yasukawa M; Yamashita M
Cancer Sci; 2018 Dec; 109(12):3737-3750. PubMed ID: 30302856
[TBL] [Abstract][Full Text] [Related]
12. Targeting glutamine metabolism enhances tumor-specific immunity by modulating suppressive myeloid cells.
Oh MH; Sun IH; Zhao L; Leone RD; Sun IM; Xu W; Collins SL; Tam AJ; Blosser RL; Patel CH; Englert JM; Arwood ML; Wen J; Chan-Li Y; Tenora L; Majer P; Rais R; Slusher BS; Horton MR; Powell JD
J Clin Invest; 2020 Jul; 130(7):3865-3884. PubMed ID: 32324593
[TBL] [Abstract][Full Text] [Related]
13. Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells.
Foy SP; Mandl SJ; dela Cruz T; Cote JJ; Gordon EJ; Trent E; Delcayre A; Breitmeyer J; Franzusoff A; Rountree RB
Cancer Immunol Immunother; 2016 May; 65(5):537-49. PubMed ID: 26961085
[TBL] [Abstract][Full Text] [Related]
14. Memory type 2 helper T cells induce long-lasting antitumor immunity by activating natural killer cells.
Kitajima M; Ito T; Tumes DJ; Endo Y; Onodera A; Hashimoto K; Motohashi S; Yamashita M; Nishimura T; Ziegler SF; Nakayama T
Cancer Res; 2011 Jul; 71(14):4790-8. PubMed ID: 21646476
[TBL] [Abstract][Full Text] [Related]
15. Combinational FLt3 ligand and granulocyte macrophage colony-stimulating factor treatment promotes enhanced tumor infiltration by dendritic cells and antitumor CD8(+) T-cell cross-priming but is ineffective as a therapy.
Berhanu A; Huang J; Alber SM; Watkins SC; Storkus WJ
Cancer Res; 2006 May; 66(9):4895-903. PubMed ID: 16651446
[TBL] [Abstract][Full Text] [Related]
16. PD-1 Blockade Unleashes Effector Potential of Both High- and Low-Affinity Tumor-Infiltrating T Cells.
Martínez-Usatorre A; Donda A; Zehn D; Romero P
J Immunol; 2018 Jul; 201(2):792-803. PubMed ID: 29875150
[TBL] [Abstract][Full Text] [Related]
17. Metabolic plasticity of metastatic breast cancer cells: adaptation to changes in the microenvironment.
Simões RV; Serganova IS; Kruchevsky N; Leftin A; Shestov AA; Thaler HT; Sukenick G; Locasale JW; Blasberg RG; Koutcher JA; Ackerstaff E
Neoplasia; 2015 Aug; 17(8):671-84. PubMed ID: 26408259
[TBL] [Abstract][Full Text] [Related]
18. Abscopal Effects With Hypofractionated Schedules Extending Into the Effector Phase of the Tumor-Specific T-Cell Response.
Zhang X; Niedermann G
Int J Radiat Oncol Biol Phys; 2018 May; 101(1):63-73. PubMed ID: 29534901
[TBL] [Abstract][Full Text] [Related]
19. CD8
Farhood B; Najafi M; Mortezaee K
J Cell Physiol; 2019 Jun; 234(6):8509-8521. PubMed ID: 30520029
[TBL] [Abstract][Full Text] [Related]
20. Checkpoint blockade immunotherapy enhances the frequency and effector function of murine tumor-infiltrating T cells but does not alter TCRβ diversity.
Kuehm LM; Wolf K; Zahour J; DiPaolo RJ; Teague RM
Cancer Immunol Immunother; 2019 Jul; 68(7):1095-1106. PubMed ID: 31104075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]